Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | IDE | P14735 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | MECP2 | P51608 | 1/20 | 0.31 |
| ▸ | MBD2 | Q9UBB5 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8558204 | 0.85 | MAPT (0.41) | KMT2AMEN1GAAMAPTRAB9A | |
| SCHEMBL17634322 | 0.83 | KMT2A (0.41) | KMT2AMEN1GAAARMAPT | |
| SCHEMBL15748613 | 0.75 | GAA (0.35) | KMT2AMEN1GAAMAPT | |
| SCHEMBL29763588 | 0.74 | TNKS2 (0.34) | KMT2AMEN1GAAARIDE | |
| SCHEMBL18562458 | 0.72 | MEN1 (0.45) | KMT2AMEN1GAAMAPTRAB9A | |
| SCHEMBL26676098 | 0.72 | MAPT (0.31) | KMT2AMEN1GAAMAPTRAB9A | |
| SCHEMBL15237630 | 0.71 | APP (0.36) | MAPTALDH1A1HSD17B10ESR2HPGD | |
| SCHEMBL16422030 | 0.70 | APAF1 (0.39) | KMT2AMEN1GAAMAPTRAB9A | |
| SCHEMBL6111309 | 0.70 | GAA (0.44) | KMT2AMEN1GAAMAPT | |
| SCHEMBL30695372 | 0.69 | PBRM1 (0.41) | KMT2AMEN1GAAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, APOL1, FABP3 | KMT2A 2842/4885MEN1 4653/4885GAA 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.